Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Genomic Vision and Cambridge Consultants, Announce the Development of an Innovative Technology Platform

Genomic Vision, a Euronext-listed biotechnology company developing tools and services for the highly accurate characterization of DNA sequences, is pleased to announce the selection of Cambridge Consutants, a world-leading product development and technology consultancy, part of Capgemini Invent1, to jointly develop the next generation of a technology platform for the analysis of structural and functional genome modifications.

Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox

The DNA combing technology, pioneered by Genomic Vision, will help achieve significantly higher throughput, reduced hands-on time and improved user experience through the collaboration. A fully integrated system, starting from DNA sample preparation to image analysis driven by Artificial Intelligence, will be developed to offer an automated workflow and excellent user experience.

Latest Aithority Insights: Got It AI Announces AutoFlows, a Breakthrough Autonomous Conversational AI

Related Posts
1 of 33,501

Genomic Vision’s DNA combing technology enables the detection of single DNA molecules and chromosomal rearrangements, identifying features of the genome that other methods cannot assess. The current technology was most suitable for research purposes. The future platform will improve performance by reaching a higher throughput compatible with pharmaceutical requirements.

“This collaboration is truly about combining the strengths of our two companies to develop a disruptive technological platform to achieve our ambitious strategic objectives,” said Andrii Kulakovskyi, Ph.D., Technical Director of Genomic Vision. “This novel platform will be a game-changer in Genomic Vision strategic plans.”

Eric Wilkinson, CEO Cambridge Consultants commented: “Genomic Vision’s technology and applications are very impressive. Together, we have all the expertise, skills and tools to significantly drive innovation in this technology to unveil genome modifications.”

Red Hat and IBM Research :  Red Hat and IBM Research Advance IT Automation with AI-Powered Capabilities for Ansible

[To share your insights with us, please write to] 

Comments are closed.